Vericel Corporation VCEL
Analyst Ratings
- Consensus
- Buy — 3 Buy · 0 Hold · 0 Sell (3 analysts)
- Avg. Price Target
- $60.67 (+42.5% upside)
Key Stats
- Today's Range
- $42.52 – $43.50
- 50-Day Range
- $37.35 – $46.01
- 52-Week Range
- $28.95 – $49.32
- Volume
- 132K shs
- Average Volume
- 535K shs
- Market Cap
- $2.22 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 2.79%
- Days to Cover
- 3.16
About Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Related Stocks
Compare head-to-head: VCEL vs AMGN·VCEL vs MRNA·VCEL vs HALO·VCEL vs RGEN
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.